Johnson & Johnson (J&J)
-
Johnson & Johnson invests US$1B to expand vision care manufacturing in Florida
The investment forms part of the company’s broader plan to spend US$55 billion on expanding its domestic manufacturing footprint through 2029.
-
Johnson & Johnson to acquire Firefly Bio for US$1B to advance KRAS-targeted cancer treatments
The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.
-
Johnson & Johnson MedTech collaborates with DoH Abu Dhabi to launch AI-powered surgical intelligence network
The initiative integrates Johnson & Johnson’s Polyphonic™ open digital ecosystem with DOH Abu Dhabi and leading technology partners, including Amazon Web Services (AWS) and NVIDIA.
-
Johnson & Johnson launches advanced Varipulse Pro Ablation System in Europe with CE Mark approval
Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.
-
Johnson & Johnson’s Icotyde earns FDA approval as first oral peptide for plaque psoriasis
Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.
-
Johnson & Johnson commits USD55B to US manufacturing expansion amid tariff concerns
The new facility will generate approximately 500 permanent biomanufacturing positions once operational.
-
Johnson & Johnson expands oncology portfolio with USD3B acquisition of Halda Therapeutics
Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.